Dual IO 2021 - Year in Review

Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma. Read More ›


The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma. Read More ›

First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma. Read More ›

In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals. Read More ›

Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates. Read More ›

Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Read More ›


Durvalumab plus either oleclumab or monalizumab improved overall response rate, progression-free survival, and 10-month progression-free survival in locally advanced, unresectable, stage III NSCLC. Read More ›

The phase 3 CheckMate-743 trial demonstrated survival improvement over 3 years with first-line nivolumab plus ipilimumab for patients with unresectable malignant pleural mesothelioma. Read More ›

Page 1 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications